49. W. do Hwang, H.Y. Ko, J.H. Lee, H. Kang, S.H. Ryu, I.C. Song et al., A nucleolin-targeted
multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J. Nucl.
Med. 51(1), 98–105 (2010)
50. I. Velikyan, Prospective of
68
Ga-radiopharmaceutical development. Theranostics 4(1), 47–
80 (2013)
51. C.J. Anderson, R. Ferdani, Copper-64 radiopharmaceuticals for PET imaging of cancer:
advances in preclinical and clinical research. Cancer Biother. Radiopharm. 24(4), 379–393
(2009)
52. A. Niccoli Asabella, G.L. Cascini, C. Altini, D. Paparella, A. Notaristefano, G. Rubini, The
copper radioisotopes: a systematic review with special interest to
64
Cu. Biomed. Res. Int.
786463 (2014)
53. G. Fischer, U. Seibold, R. Schirrmacher, B. Wangler, C. Wangler,
89
Zr, a radiometal nuclide
with high potential for molecular imaging with PET: chemistry, applications and remaining
challenges. Molecules 18(6), 6469–6490 (2013)
54. B.L.R. Kam, J.J.M. Teunissen, E.P. Krenning, W.W. de Herder, S. Khan, E.I. van Vliet
et al., Lutetium-labeled peptides for therapy of neuroendocrine tumours. Eur. J. Nucl. Med.
Mol. Imaging 39(1), 103–112 (2012)
55. A. Sainz-Esteban, V. Prasad, C. Schuchardt, C. Zachert, J.M. Carril, R.P. Baum,
Comparison of sequential planar
177
Lu-DOTA-TATE dosimetry scans with
68
Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours
undergoing peptide receptor radionuclide therapy. Eur. J. Nucl. Med. Mol. Imaging 39(3),
501–511 (2012)
56. V. Goffredo, A. Paradiso, G. Ranieri, C.D. Gadaleta, Yttrium-90 (
90
Y) in the principal
radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy,
radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience
(1999–2009). Crit. Rev. Oncol. Hematol. 80(3), 393–410 (2011)
57. H. Hong, Y. Zhang, J. Sun, W. Cai, Molecular imaging and therapy of cancer with
radiolabeled nanoparticles. Nano Today. 4(5), 399–413 (2009)
58. J.M. Jeong, J.K. Chung, Therapy with
188
Re-labeled radiopharmaceuticals: an overview of
promising results from initial clinical trials. Cancer Biother. Radiopharm. 18(5), 707–717
(2003)
59. L. Tian, Q. Chen, X. Yi, G. Wang, J. Chen, P. Ning et al., Radionuclide I-131 labeled
albumin-paclitaxel nanoparticles for synergistic combined chemo-radioisotope therapy of
cancer. Theranostics 7(3), 614–623 (2017)
60. M.E. Akerman, W.C. Chan, P. Laakkonen, S.N. Bhatia, E. Ruoslahti, Nanocrystal targeting
in vivo. Proc. Natl. Acad. Sci. U S A 99(20), 12617–12621 (2002)
61. J.V. Jokerst, T. Lobovkina, R.N. Zare, S.S. Gambhir, Nanoparticle PEGylation for imaging
and therapy. Nanomed. (Lond.) 6(4), 715–728 (2011)
62. L.E. van Vlerken, T.K. Vyas, M.M. Amiji, Poly(ethylene glycol)-modified nanocarriers for
tumor-targeted and intracellular delivery. Pharm. Res. 24(8), 1405–1414 (2007)
63. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the
EPR effect in macromolecular therapeutics: a review. J. Control Release 65(1–2), 271–284
(2000)
64. G.S. Kwon, Polymeric micelles for delivery of poorly water-soluble compounds. Crit. Rev.
Ther. Drug Carr. Syst. 20(5), 357–403 (2003)
65. Y. Barenholz, Doxil(R)–the first FDA-approved nano-drug: lessons learned. J. Control
Release 160(2), 117–134 (2012)
66. J. Nam, N. Won, J. Bang, H. Jin, J. Park, S. Jung et al., Surface engineering of inorganic
nanoparticles for imaging and therapy. Adv. Drug Deliv. Rev. 65(5), 622–648 (2013)
67. R.P. Baum, V. Prasad, D. Müller, C. Schuchardt, A. Orlova, A. Wennborg et al., Molecular
imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic
111
In- or
68
Ga-labeled affibody molecules. J. Nucl. Med. 51(6), 892–897 (2010)
11 Radiolabeling Method: Core/Surface Labeling, Chemical …
225
multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J. Nucl.
Med. 51(1), 98–105 (2010)
50. I. Velikyan, Prospective of
68
Ga-radiopharmaceutical development. Theranostics 4(1), 47–
80 (2013)
51. C.J. Anderson, R. Ferdani, Copper-64 radiopharmaceuticals for PET imaging of cancer:
advances in preclinical and clinical research. Cancer Biother. Radiopharm. 24(4), 379–393
(2009)
52. A. Niccoli Asabella, G.L. Cascini, C. Altini, D. Paparella, A. Notaristefano, G. Rubini, The
copper radioisotopes: a systematic review with special interest to
64
Cu. Biomed. Res. Int.
786463 (2014)
53. G. Fischer, U. Seibold, R. Schirrmacher, B. Wangler, C. Wangler,
89
Zr, a radiometal nuclide
with high potential for molecular imaging with PET: chemistry, applications and remaining
challenges. Molecules 18(6), 6469–6490 (2013)
54. B.L.R. Kam, J.J.M. Teunissen, E.P. Krenning, W.W. de Herder, S. Khan, E.I. van Vliet
et al., Lutetium-labeled peptides for therapy of neuroendocrine tumours. Eur. J. Nucl. Med.
Mol. Imaging 39(1), 103–112 (2012)
55. A. Sainz-Esteban, V. Prasad, C. Schuchardt, C. Zachert, J.M. Carril, R.P. Baum,
Comparison of sequential planar
177
Lu-DOTA-TATE dosimetry scans with
68
Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours
undergoing peptide receptor radionuclide therapy. Eur. J. Nucl. Med. Mol. Imaging 39(3),
501–511 (2012)
56. V. Goffredo, A. Paradiso, G. Ranieri, C.D. Gadaleta, Yttrium-90 (
90
Y) in the principal
radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy,
radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience
(1999–2009). Crit. Rev. Oncol. Hematol. 80(3), 393–410 (2011)
57. H. Hong, Y. Zhang, J. Sun, W. Cai, Molecular imaging and therapy of cancer with
radiolabeled nanoparticles. Nano Today. 4(5), 399–413 (2009)
58. J.M. Jeong, J.K. Chung, Therapy with
188
Re-labeled radiopharmaceuticals: an overview of
promising results from initial clinical trials. Cancer Biother. Radiopharm. 18(5), 707–717
(2003)
59. L. Tian, Q. Chen, X. Yi, G. Wang, J. Chen, P. Ning et al., Radionuclide I-131 labeled
albumin-paclitaxel nanoparticles for synergistic combined chemo-radioisotope therapy of
cancer. Theranostics 7(3), 614–623 (2017)
60. M.E. Akerman, W.C. Chan, P. Laakkonen, S.N. Bhatia, E. Ruoslahti, Nanocrystal targeting
in vivo. Proc. Natl. Acad. Sci. U S A 99(20), 12617–12621 (2002)
61. J.V. Jokerst, T. Lobovkina, R.N. Zare, S.S. Gambhir, Nanoparticle PEGylation for imaging
and therapy. Nanomed. (Lond.) 6(4), 715–728 (2011)
62. L.E. van Vlerken, T.K. Vyas, M.M. Amiji, Poly(ethylene glycol)-modified nanocarriers for
tumor-targeted and intracellular delivery. Pharm. Res. 24(8), 1405–1414 (2007)
63. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the
EPR effect in macromolecular therapeutics: a review. J. Control Release 65(1–2), 271–284
(2000)
64. G.S. Kwon, Polymeric micelles for delivery of poorly water-soluble compounds. Crit. Rev.
Ther. Drug Carr. Syst. 20(5), 357–403 (2003)
65. Y. Barenholz, Doxil(R)–the first FDA-approved nano-drug: lessons learned. J. Control
Release 160(2), 117–134 (2012)
66. J. Nam, N. Won, J. Bang, H. Jin, J. Park, S. Jung et al., Surface engineering of inorganic
nanoparticles for imaging and therapy. Adv. Drug Deliv. Rev. 65(5), 622–648 (2013)
67. R.P. Baum, V. Prasad, D. Müller, C. Schuchardt, A. Orlova, A. Wennborg et al., Molecular
imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic
111
In- or
68
Ga-labeled affibody molecules. J. Nucl. Med. 51(6), 892–897 (2010)
11 Radiolabeling Method: Core/Surface Labeling, Chemical …
225